{"classes":[{"categories":[{"measurements":[{"comment":"The upper limit of the 95% CI was not estimable due to the small number of events.","groupId":"OG000","lowerLimit":"37.7","upperLimit":"NA","value":"39.6"},{"groupId":"OG001","lowerLimit":"30.9","upperLimit":"41.3","value":"38.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"933"},{"groupId":"OG001","value":"468"}],"units":"Participants"}],"description":"Chemotherapy-free disease-specific survival was defined as the time from randomization to first use of cytotoxic chemotherapy for prostate cancer or death due to prostate cancer as assessed by the investigator. Participants not starting treatment with a cytotoxic chemotherapy or not known to have died due to prostate cancer at the time of analysis were right censored at the date of last assessment before the analysis data cutoff date for the purposes of analysis. Analysis was based on Kaplan-Meier estimates.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received 4 capsules of Enzalutamide 40 mg each (total dose 160 mg per day) orally, once daily in double-blind and open-label phase (up to a maximum of 68.8 months) until radiographic progression. Participants after last dose of study drug, were followed up for safety up to 30 days, and were long term followed up (for survival status and new prostate cancer therapies) from last dose to the death date or last known survival date.","id":"OG000","title":"Enzalutamide 160 mg"},{"description":"Participants received 4 capsules of placebo (matched to Enzalutamide) orally, once daily in double blind phase (up to a maximum of 51.3 months) until radiographic progression. Participants were given an opportunity to switch to open-label enzalutamide after completion of double blind phase. Participants after last dose of study drug, were followed up for safety up to 30 days and were long term followed up (for survival status and new prostate cancer therapies) to the death date or last known survival date.","id":"OG001","title":"Placebo"}],"paramType":"MEDIAN","populationDescription":"The ITT population was defined as all participants randomly assigned to study treatment and was based on randomized treatment assignment regardless of whether or not treatment was administered.","reportingStatus":"POSTED","timeFrame":"From randomization up to first use of cytotoxic chemotherapy for prostate cancer or death due to prostate cancer (until the data cut-off date of 28 June 2017, maximum duration of treatment: 42.8 months)","title":"Chemotherapy-Free Disease Specific Survival","type":"SECONDARY","unitOfMeasure":"months"}